FDA Clears Ocugen’s Phase II/III Trial for Stargardt Disease Gene Therapy
Ocugen’s OCU410ST gene therapy gets another green light. Next stop: a Phase II/III trial. The U.S. Food and Drug Administration…
ViGeneron Rebrands as VeonGen Therapeutics, Accelerates Clinical Pipeline in IRDs
VeonGen Therapeutics debuts with FDA recognition and bold plans for inherited eye diseases. ViGeneron (Munich, Germany) announced its rebranding as…
latest posts
